Proactive Investors - Run By Investors For Investors

Ellex Medical Lasers promotes glaucoma surgery device in China

Ellex Medical Lasers (ASX:ELX) has commenced clinical training of physicians in China in the use of the Ellex iTrack™ minimally invasive glaucoma surgery (MIGS) device.
Ellex Medical Lasers promotes glaucoma surgery device in China
Ellex Medical Lasers promotes glaucoma surgery device in China

iTrack is an illuminated, micron-scale microcatheter, which enables physicians to perform canaloplasty for glaucoma patients.

This is the first program of clinical training in China for physicians in the ab interno canaloplasty (ABiC) technique using iTrack.

To date, sales in China have been limited because only the more complex ABiC surgery technique has been marketed.

Ellex’s program in China to relaunch iTrack for the simpler, faster ABiC technique is expected to be well received.

The training programs will be conducted at leading hospitals and teaching institutions in Shanghai and Beijing during 12-17 December 2016.

It is worth noting that Ellex iTrack™ is the only MIGS device in the world currently approved by the Chinese medical device regulatory authority for sale in China.

The current spend in China for the treatment of eye diseases is expected to double over the next five years, growing at a CAGR of 15% to reach US$5.3 billion per annum by 2021.

This growing demand, combined with strong global interest in MIGS, offers a favourable market outlook for Ellex iTrack.

Earlier this month, Ellex raised $10.3 million from a placement of shares with Australian and New Zealand investors, at $1.46 per share.

The funds will be used to accelerate the development of the company’s MIGS business focussed on the U.S. and Chinese markets.

View full ELX profile View Profile

Ellex Medical Lasers Timeline

Newswire
November 30 2016

Related Articles

myLotus testing kit
October 31 2018
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls
cancer
May 14 2018
Physiomics' share price surged on a €500,000 contract for its virtual tumour software with Merck KgaA.
cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use